CD47 and COVID-19: Studies have shown that simultaneous blockade of IL-6, CD47, and PD-L1 attenuates pulmonary fibrosis and may be associated with enhanced phagocytosis of fibroblasts and elimination of inhibition of adaptive immunity [76].In patients with COVID-19 combined with pulmonary fibrosis, and IL-6 antibodies showed better efficacy against COVID-19-induced cytokine storm.